Immatics N.v. · NASDAQ:IMTX
Immatics — Investor Presentation (June 2022)
54 slides from Immatics's investor presentation, Jun 2, 2022
Slide 1: Immatics Corporate Presentation
Immatics Corporate Presentation June 02, 2022 Exhibit 99.3
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation (“Presentation”) is provided by Immatics N.V. (“Immatics” or the “Company”) for informational purposes only. The information contained herein does not purport to be all-inclusive and Immatics nor any of its affiliates nor any of its or their control perso
Slide 3: Building a Leading TCR Therapeutics Company
Building a Leading TCR Therapeutics Company Intro Clinical PoC for Cell Therapy Objective responses across multiple solid tumors in early TCR-T clinical development Differentiated Approach Unique technologies to identify true cancer targets and right TCRs Strategic Partnerships World-leading industr
Slide 4: Our TCR-based Approaches Leverage the Full Target Space beyond the Cancer Cell Surface
Our TCR-based Approaches Leverage the Full Target Space beyond the Cancer Cell Surface Intro
Slide 5: Two TCR-based Therapeutic Modalities
Two TCR-based Therapeutic Modalities Distinct mechanisms of actions and therapeutic application to address the needs of a broad patient population at different stages of disease and with different types of tumors Intro
Slide 6: Our Pipeline of TCR-based Adoptive Cell Therapies and Bispecifics
Modality Product Candidate Target Preclinical Phase 1a1 Phase 1b1 Phase 2/3 ACTengine® Autologous ACT IMA203 PRAME IMA203CD8 PRAME IMA201 MAGEA4/8 IMA204 COL6A3 Autologous ACT 4 programs Undisclosed 2 programs Undisclosed ACTallo® Allogeneic ACT IMA30x Undisclosed 2 programs Undisclosed TCER® Bispec
Slide 7: Strategic Collaborations
Strategic Collaborations Synergistic Expertise that Can Foster Transformative Innovations for ACT and Bispecifics Research collaboration to develop bispecific immunotherapies 3 Immatics targets $54 M upfront Co-promotion option Broadening the clinical framework beyond our pipeline Research collabora
Slide 8: Immatics and Bristol Myers Squibb – New Allogeneic Multi-program Collaboration
Immatics and Bristol Myers Squibb – New Allogeneic Multi-program Collaboration Leveraging Complementary Technologies & Capabilities for the Benefit of Cancer Patients Off-the-shelf allogeneic TCR-T/CAR-T therapies for patients with solid cancers Activities for initial 2 BMS programs: Clinical develo
Slide 9: Selected solid cancer indications with significant target prevalence
IMA201 / IMA401 IMA202* IMA203 / IMA402 IMA204 MAGEA4/8 MAGEA1 PRAME COL6A3 exon 6 Selected solid cancer indications with significant target prevalence1 Sarcoma Subtypes – up to 80% Squamous NSCLC – 50% HNSCC – 35% Bladder Carcinoma – 30% Esophageal Carcinoma – 25% Uterine Carcinosarcoma – 25% Ovari
Slide 10: Key Features of Our Clinical ACTengine Programs
IMA201 IMA202* IMA203 Peptide Target HLA-A*02-presented peptide derived from MAGEA4/8 MAGEA1 PRAME shown to be naturally and specifically presented on native tumor tissues at differentiated high peptide target density1 100-1,000 copies/cell 50-900 copies/cell 100-1,000 copies/cell T cell Receptor (T
Slide 11: ACTengine IMA203 – TCR-T Targeting PRAME
ACTengine® IMA203 – TCR-T Targeting PRAME
Slide 12: ACTengine IMA203 – TCR-T Targeting PRAME
ACTengine® IMA203 – TCR-T Targeting PRAME Broadly Expressed Target on Multiple Solid Cancers Combined with Highly Specific TCR HLA-A*02-presented peptide derived from PRAME Naturally and specifically presented on tumors at high target density1: 100-1,000 copies/cell Identified and validated by XPRES
Slide 13: ACTengine IMA203 Targeting PRAME – Mechanism of Action
ACTengine® IMA203 Targeting PRAME – Mechanism of Action Immatics’ Leading TCR-T Approach IMA203
Slide 14: Optimized Cell Therapy Products to Enhance T cell Persistence & Efficacy
Optimized Cell Therapy Products to Enhance T cell Persistence & Efficacy Current Proprietary Manufacturing Protocol for ACTengine® Product Candidates Proprietary Manufacturing Process, designed to reduce manufacturing process to approx. 1 week shorten vein-to-vein time generate younger T cells with
Slide 15: ACTengine IMA203 – Patient Flow
ACTengine® IMA203 – Patient Flow HLA-A*02 Testing Blood sample; Central lab Treatment & Observation Phase Long Term Follow-up Screening & Manufacturing Phase ACTengine® Manufacturing by Immatics Infusion of ACTengine® T cell Product Lymphodepletion 30 mg/m2 Fludarabine1 and 500 mg/m2 Cyclophosphamid
Slide 16: ACTengine IMA203 – Key Objectives & Trial Design
ACTengine® IMA203 – Key Objectives & Trial Design Presented at SITC Conference as Late-Breaking Presentation (Cut-off October 05, 2021) Trial Design & Recruitment Status 1 Enrichment cohorts EC1 & EC2: patients infused with intermediate doses enabling infusion of patients with medical need during do
Slide 17: ACTengine IMA203 – Safety Profile
ACTengine® IMA203 – Safety Profile Manageable & Transient Treatment-emergent Adverse Events – No ≥ Grade 3 CRS or ICANS Adverse event All grades ≥ Grade 3 No. % No. % Patients with any adverse event 19 100.0 19 100.0 Adverse Events of Special interest Cytokine release syndrome 17 89.5 0 0.0 ICANS2 4
Slide 18: ACTengine IMA203 – Change in Target Lesions
ACTengine® IMA203 – Change in Target Lesions Objective Responses across Multiple Tumor Types at Doses below 1 billion Transduced Cells 1 RECIST1.1 response at the timepoint of maximum change of target lesions (week 12): PD due to new lesions (leptomeningeal disease) at week 12 2 Patients dosed with
Slide 19: ACTengine IMA203 – Response Over Time
Patient ID Indication Dose 203-DL1-01 Head & Neck Cancer DL1 203-DL1-02 Head & Neck Cancer DL1 203-DL1-03 Ovarian Cancer DL1 203-EC1-01 Melanoma EC1 203-EC1-02 Melanoma EC1 203-EC1-03 Uveal Melanoma EC1 203-DL2-01 Synovial Sarcoma DL2 203-DL2-02 Synovial Sarcoma DL2 203-DL2-03 Synovial Sarcoma DL2 2
Slide 20: ACTengine IMA203 – Engraftment, Persistence & Tumor Infiltration
ACTengine® IMA203 – Engraftment, Persistence & Tumor Infiltration Clinical Responses Consistent with Biological Data T cell Engraftment & Persistence Tumor Infiltration post Infusion2 1 Mann-Whitney U test, p=0.065; 2 Post infusion biopsies at week 6 (except one patient with SD at week 3); 3 Mann-Wh
Slide 21: ACTengine IMA203 – Case Study Patient IMA203-DL3-01
ACTengine® IMA203 – Case Study Patient IMA203-DL3-01 Confirmed Partial Response with Deepening Tumor Regression in Multiple Lesions Liver metastasis Lung metastasis Sub cut. metastasis Change in Target Lesions T cell Persistence & Peak Response in the Blood 62-year-old female; metastatic uveal melan
Slide 22: Preliminary Findings after Completion of Dose Level 3
Preliminary Findings after Completion of Dose Level 3 ACTengine® IMA203 PRAME – Phase 1a Dose Escalation Interim Update 1 DLT: dose-limiting toxicity, since March 17, 2021 (reported DLT at DL2); 2 CRS: cytokine release syndrome, ICANS: Immune effector cell-associated neurotoxicity syndrome, both gra
Slide 23: Our Plans to Achieve Long-Lasting Responses with TCR-T cells against PRAME
Our Plans to Achieve Long-Lasting Responses with TCR-T cells against PRAME Phase 1b Cohort A: IMA203 Monotherapy at Target Dose1 Phase 1b Cohort B: IMA203 at Target Dose plus Checkpoint Inhibitor3 Phase 1b Cohort C: IMA203CD8 2nd Gen Phase 1a: IMA203 Monotherapy Dose Escalation in Basket Trial Addre
Slide 24: ACTengine IMA203CD8 – Next-generation TCR-T
ACTengine® IMA203CD8 – Next-generation TCR-T Building on First-Gen IMA203 Success to Further Improve Anti-Tumor Activity Engagement of CD4 T cells by CD8 co-transduction reported to boost anti-tumor activity in TCR-T trials Recent data from leukaemia patients treated with CAR-T achieving decade-long
Slide 25: ACTengine IMA203CD8 – Preclinical Assessment of Anti-Tumor Efficacy
ACTengine® IMA203CD8 – Preclinical Assessment of Anti-Tumor Efficacy Co-Transduction of CD8 Enhances Anti-Tumor Activity in Vitro IMA203CD8 TCR IMA203 TCR Non-Transduced Control Serial Killing Assay – CD8 & CD4 T cells Engagement of CD4 T cells may enhance depth and durability of anti-tumor response
Slide 26: ACTengine IMA201 Targeting MAGEA4/8
ACTengine® IMA201 Targeting MAGEA4/8 Key Features HLA-A*02-presented peptide derived from MAGEA4 and/or MAGEA/8 >5-fold higher peptide copy number per tumor cell than a commonly used MAGEA4 target Naturally and specifically presented on tumors at high target density1: 100-1,000 copies/cell Identifie
Slide 27: ACTengine IMA204 First-in-Class TCR-T Targeting Tumor Stroma
ACTengine® IMA204 First-in-Class TCR-T Targeting Tumor Stroma Key Features HLA-A*02-presented peptide derived from COL6A3 exon 6 Naturally and specifically presented on tumors at high target density1: 100-700 copies/cell Novel tumor stroma target identified and validated by XPRESIDENT® quant. mass s
Slide 28: ACTengine IMA204 – High Affinity, CD8-independent TCR
ACTengine® IMA204 – High Affinity, CD8-independent TCR Complete Tumor Eradication in vitro & in vivo1 by Affinity-enhanced IMA204 TCR CD8-independent TCR leads to tumor eradication in all mice treated Control IMA204 TCR D7 D16 D22 D29 Affinity maturated CD8-independent, next-generation TCR engages b
Slide 29: ACTallo – Immatics' Allogeneic Cell Therapy Approach
ACTallo® – Immatics’ Allogeneic Cell Therapy Approach Off-the-shelf cell therapy, no need for personalized manufacturing à reduced logistics and time to application Potential for hundreds of doses from one single donor leukapheresis à lower cost of goods Use of healthy donor material provides standa
Slide 30: Why γδ T cells?
Why γδ T cells? γδ T cells Are Well Suited for an Off-the-shelf Cell Therapy Approach γδ T cells are abundant in the peripheral blood show intrinsic anti-tumor activity naturally infiltrate solid tumors & correlate with favorable prognosis are HLA-independent, thus do not cause graft-vs-host disease
Slide 31: TCER — TCR Bispecifics
oe Immatics TCER® — TCR Bispecifics
Slide 32: TCER – Mechanism of Action
TCER® – Mechanism of Action Immatics’ Off-the-Shelf TCR Bispecifics Approach TCER®
Slide 33: TCER – Immatics' Half-Life Extended Bispecifics
TCER® – Immatics’ Half-Life Extended Bispecifics pHLA targeting TCR High-affinity TCR targeting HLA-restricted tumor-specific peptides Broad therapeutic window through XPRESIDENT®-guided affinity maturation (>1000x)1 Complete tumor eradication in mouse xenograft models at low doses T cell recruiting
Slide 34: TCER – Development of a Proprietary TCR Bispecific Format
TCER® – Development of a Proprietary TCR Bispecific Format Flexible Plug-and-play Platform Designed to Efficiently Generate New TCR Bispecifics Immatics developed a proprietary TCR Bispecific format for specific targeting of tumor-specific pHLA at low copy numbers TCER® format successfully validated
Slide 35: Potency of Our Proprietary TCR Bispecific Format TCER
Potency of Our Proprietary TCR Bispecific Format TCER® Seven different TCR Bispecific formats were evaluated with a pHLA targeting TCR and the identical T cell recruiting antibody TCER® format had higher combination of potency and specificity1 than six alternative TCR Bispecific format designs evalu
Slide 36: TCER Portfolio
TCER® Portfolio Building a Pipeline of Next-Gen Half-Life Extended TCR Bispecifics IMA401 IMA402 IMA40X MAGEA4/8 PRAME Undisclosed Status Start of Phase 1 trial in May 2022 Clinical GMP batch targeted in 2022 Phase 1 trial in 2023 TCER® engineering and preclinical testing ongoing Preclincial Proof-o
Slide 37: Phase 1 Clinical Trial to Evaluate TCER IMA401 Targeting MAGEA4/8
Phase 1 Clinical Trial to Evaluate TCER® IMA401 Targeting MAGEA4/8 Trial Overview Primary Objective Biomarker positive patients with recurrent and/or refractory solid tumors HLA-A*02:01 MAGEA4/8 (Immatics’ IMADetect® test) Basket trial in indications with high MAGEA4/8 prevalence, e.g. sqNSCLC, SCLC
Slide 38: Phase 1 Clinical Trial to Evaluate TCER IMA401 Targeting MAGEA4/8
Phase 1 Clinical Trial to Evaluate TCER® IMA401 Targeting MAGEA4/8 MTD: maximum tolerated dose, RP2D: recommended phase 2 dose; MABEL: minimum anticipated biological effect level; BLRM: Bayesian logistic regression model; 1 Pharmacokinetics data assessed throughout the trial might provide an opportu
Slide 39: TCER IMA401 Targeting MAGEA4/8
TCER® IMA401 Targeting MAGEA4/8 Product Candidate in Clinical Development with Bristol Myers Squibb Treatment schedule Tumor Model in Mice1 Complete remissions observed in all animals even at low IMA401 dose of 0.05 mg/kg No detectable outgrowth of tumors during prolonged observation period of 70 da
Slide 40: TCER IMA402 Targeting PRAME
TCER® IMA402 Targeting PRAME Preclinical-stage Product Candidate Fully Owned by Immatics PRAME Target Peptide HLA-A*02-restricted PRAME peptide targeted by TCER® IMA402 is one of the most frequently expressed intracellular cancer targets for TCR-based therapies Homogenously expressed at high prevale
Slide 41: TCER IMA402 – Efficacy Assessment in Tumor Model in Mice
TCER® IMA402 – Efficacy Assessment in Tumor Model in Mice Superior Tumor Control Using a Proprietary, Low-Affinity Recruiter Widely used T cell recruiting Ab (3 variants) medium to high affinity Treatment schedule N=6 mice per group, two PBMC donors Dose: 0.025 mg/kg Proprietary, low-affinity T cell
Slide 42: TCER IMA402 – In vitro Safety Assessment with Normal Tissue Cells
TCER® IMA402 – In vitro Safety Assessment with Normal Tissue Cells Cytotoxicity against N≥9 different human normal tissue cell types TCER® IMA402 shows a minimum of 1,000-fold therapeutic window between normal tissue cell reactivity and tumor cell reactivity Normal Tissue Type Therapeutic Window (x-
Slide 43: Immatics' Proprietary Target and TCR Discovery Platforms
Immatics’ Proprietary Target and TCR Discovery Platforms
Slide 44: True Cancer Targets & Matching Right TCRs
True Cancer Targets & Matching Right TCRs Goal to Maximize Anti-Tumor Activity and Minimize Safety Risks of TCR-based Immunotherapies True Targets via XPRESIDENT® technology platform are naturally presented on tumor tissues as identified by mass-spec are absent or presented at only low levels on nor
Slide 45: Immatics' Unique Capability – Identification of the most Relevant Target
Immatics’ Unique Capability – Identification of the most Relevant Target Example of MAGEA4/8 Peptide Target 1 Copy number per tumor cell (CpC) measured on a paired-sample basis by AbsQuant®, i.e. comparing MAGEA4 vs. MAGEA4/A8 peptide presentation on same sample, 2 Students paired T test p<0.0012 Te
Slide 46: Pool of Prioritized Targets as Foundation for Future Value Generation
Technology Pool of 200 Prioritized Targets as Foundation for Future Value Generation 200 Prioritized Targets Grouped in 3 Target Classes: Well known and characterized parent protein (20%) e.g. MAGE family cancer testis antigens Unknown or poorly characterized parent protein (60%) e.g. stroma target
Slide 47: Development of the Right TCR – XCEPTOR Technology
Development of the Right TCR – XCEPTOR® Technology TCR Discovery and Engineering for ACT and TCR Bispecifics TCR Bispecifics T cell engaging receptor (TCER®) Adoptive Cell Therapy ACTengine® ACTallo® Fast, efficient and highly sensitive discovery of highly specific, natural TCRs Protein engineering
Slide 48: Optimal Target Selection & TCR Specificity for Minimizing Safety Risks
Optimal Target Selection & TCR Specificity for Minimizing Safety Risks Unique Interplay between Technology Platforms Allows Early De-risking for Clinical Development Target peptide presented on tumor cells Selective killing of tumor cells Target peptide presented on normal cells Off-target toxicity
Slide 49: Corporate Information & Milestones
Corporate Information & Milestones
Slide 50: Experienced Global Leadership Team Across Europe and the US
Experienced Global Leadership Team Across Europe and the US Harpreet Singh Chief Executive Officer Co-Founder >20 yrs biotech experience Carsten Reinhardt Chief Development Officer >20 yrs pharma & biotech experience (Micromet, Roche, Fresenius) Rainer Kramer Chief Business Officer 25 yrs pharma & b
Slide 51: Strong, Focused and Highly Integrated Trans-Atlantic Organization
Strong, Focused and Highly Integrated Trans-Atlantic Organization Senior Leadership, Business Development, Clinical Operations, Intellectual Property, Regulatory Affairs, Communications Senior Leadership, Research and Development (Adoptive Cell Therapy), CMC, Clinical Operations, Regulatory Affairs,
Slide 52: Robust IP Portfolio
Robust IP Portfolio Immatics’ Patent Estate – Territorial Coverage Cancer targets, TCRs and technology protected by: 5,800 applications and patents filed in all major countries and regions >120 patent families >2,000 granted patents, thereof >490 granted patents in the US Corporate
Slide 53: Near-Term Value Drivers and Development Milestones
Near-Term Value Drivers and Development Milestones Clinical Expansion of TCR Bispecifics and the Next-generation of TCR-T Leverage full potential of targeting PRAME Focused & accelerated development of IMA203 expansion cohorts Develop IMA402, an off-the-shelf TCER® Advance clinical development of AC
Slide 54: Delivering the Power of T Cells to Cancer Patients
www.immatics.com Olin] ¥| DELIVERING THE POWER OF T CELLS TO CANCER PATIENTS oe Immatics